Anticancer Therapy Targeting Cancer-Derived Extracellular Vesicles

ACS Nano. 2024 Mar 5;18(9):6748-6765. doi: 10.1021/acsnano.3c06462. Epub 2024 Feb 23.

Abstract

Extracellular vesicles (EVs) are natural lipid nanoparticles secreted by most types of cells. In malignant cancer, EVs derived from cancer cells contribute to its progression and metastasis by facilitating tumor growth and invasion, interfering with anticancer immunity, and establishing premetastasis niches in distant organs. In recent years, multiple strategies targeting cancer-derived EVs have been proposed to improve cancer patient outcomes, including inhibiting EV generation, disrupting EVs during trafficking, and blocking EV uptake by recipient cells. Developments in EV engineering also show promising results in harnessing cancer-derived EVs as anticancer agents. Here, we summarize the current understanding of the origin and functions of cancer-derived EVs and review the recent progress in anticancer therapy targeting these EVs.

Keywords: Biomaterials; Cancer Vaccine; Cancer metastasis; Cancer therapy; Drug delivery; Extracellular vesicles; Immunotherapy; Nanomedicine.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / metabolism
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Biological Transport
  • Extracellular Vesicles* / metabolism
  • Humans
  • Neoplasms* / pathology

Substances

  • Antineoplastic Agents